Development of vaccines for influenza disease: Opportunity costs of the COVID-19 pandemic.

Wiemken, Timothy L; Rutschman, Ana Santos

Wiemken, Timothy L; Rutschman, Ana Santos.

Wiemken TL; Saint Louis University School of Medicine, Department of Health and Clinical Outcomes Research, United States; Saint Louis University School of Medicine, Department of Medicine, Division of Infectious Diseases, Allergy, and Immunology, United States; Saint Louis University Health Innovation and Legal Preparedness Partnership, United States. Electronic address: timothy.wiemken@health.slu.edu.
Rutschman AS; Saint Louis University Health Innovation and Legal Preparedness Partnership, United States; Saint Louis University School of Law, Center for Health Law Studies, United States; Saint Louis University School of Law, Center for International and Comparative Law, United States.

Vaccine ; 39(7): 1025-1026, 2021 02 12.

Article in English | MEDLINE | ID: covidwho-1014874

Subject(s)

COVID-19; Influenza Vaccines; Influenza, Human; Pandemics; Humans; Influenza, Human/epidemiology; Influenza, Human/prevention & control; Pandemics/prevention & control

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / Pandemics / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google